ÎÚÑ»´«Ã½

Association seen regardless of participants’ smoking status and in those with no prior lung disease (WASHINGTON, Dec. 17, 2024) – People exposed to higher concentrations of three types of air pollution over a period of nearly 17 years ha...

Patients on tafasitamab had a 57% improvement in progression-free survival compared to the control arm LBA-1: Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase III Study (inMIND) (SAN D...

Transplant recipients show better physical, school, and social functioning than those receiving transfusions and medications alone LBA-5: Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Co...

Transplant shows no difference in overall or progression-free survival compared with maintenance therapy alone LBA-6: Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Co...

Variants could serve as biomarker to inform prognosis or guide treatment decisions LBA-4: Andean Enriched NFKB1 Haplotype Reduces Inflammation and Improves Response to Ropeginterferon Alfa-2b in Polycythemia Vera (PV) and Essential Thrombocythemia (E...

Surveys and focus groups find little integration of DEI principles, yield actionable recommendations (SAN DIEGO, Dec. 9, 2024) — The ÎÚÑ»´«Ã½ (ASH) leveraged its convening power to launch an initiative for identifying ba...

Program is implementable and scalable despite resource and disease burden challenges (SAN DIEGO, Dec. 8, 2024) — A multi-country newborn screening program for sickle cell disease (SCD) in sub-Saharan Africa proved feasible despite resource cons...

Advances across continuum of care show promise and hope for patients (SAN DIEGO—Dec. 8, 2024) — Studies being presented at the 66th ÎÚÑ»´«Ã½ (ASH) Annual Meeting and Exposition highlight progress in preventing and...

Study establishes groundwork for understanding the cost-effectiveness of neutrophil testing (SAN DIEGO, Dec. 7, 2024) — Universal testing for Duffy status for toddlers ages 9-12 months can be a potentially cost-effective intervention for the U.S. po...

ASH Research Collaborative study finds that only one-quarter of patients living with SCD are prescribed a DMT (SAN DIEGO, December 7, 2024) — Disease-modifying therapies (DMTs), particularly newer ones, for sickle cell disease (SCD) are substantia...